[go: up one dir, main page]

MX2010002025A - Secuencias y composiciones peptidicas. - Google Patents

Secuencias y composiciones peptidicas.

Info

Publication number
MX2010002025A
MX2010002025A MX2010002025A MX2010002025A MX2010002025A MX 2010002025 A MX2010002025 A MX 2010002025A MX 2010002025 A MX2010002025 A MX 2010002025A MX 2010002025 A MX2010002025 A MX 2010002025A MX 2010002025 A MX2010002025 A MX 2010002025A
Authority
MX
Mexico
Prior art keywords
sequences
polypeptides
protein
vertebrate
polypeptide
Prior art date
Application number
MX2010002025A
Other languages
English (en)
Inventor
Gregory Alan Stoloff
Wilson Romero Caparros-Wanderley
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of MX2010002025A publication Critical patent/MX2010002025A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/005Trypanosoma antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806Antigenic peptides or proteins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855Proteins from animals other than mammals or birds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855Proteins from animals other than mammals or birds
    • Y10S530/858Proteins from animals other than mammals or birds insects; venom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporciona una composición polipeptídica que comprende uno o más polipéptidos, polipéptidos los cuales son inmunogénicos en un vertebrado de modo que hace que el vertebrado produzca células del sistema inmune capaces de reconocer al menos un epítope de una fracción de proteína de saliva de artrópodo, donde la fracción de proteína de saliva tiene una masa de 40kDa o menos, y donde los polipéptidos son seleccionados independientemente de:las secuencias polipeptídicas de SEQ ID 1-44 o subsecuencias de esas secuencias, las subsecuencias tienen 7 aminoácidos o más; ode las secuencias polipeptídicas que tienen una homología del 85% o más con una o más de las secuencias anteriores y contenidas en una o más de las siguientes bases de datos: GenBank, Protein Data Bank (PDB), SwissProt, Protein Information Resource, (PIR), protein Research Foundation (PRF), y traducciones de CDS de esas.
MX2010002025A 2007-09-13 2008-09-05 Secuencias y composiciones peptidicas. MX2010002025A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0717864.3A GB0717864D0 (en) 2007-09-13 2007-09-13 Peptide sequences and compositions
PCT/EP2008/061824 WO2009034041A2 (en) 2007-09-13 2008-09-05 Peptide sequences and compositions

Publications (1)

Publication Number Publication Date
MX2010002025A true MX2010002025A (es) 2010-03-15

Family

ID=38658898

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002025A MX2010002025A (es) 2007-09-13 2008-09-05 Secuencias y composiciones peptidicas.

Country Status (25)

Country Link
US (2) US8986703B2 (es)
EP (4) EP2567706A3 (es)
JP (3) JP2010539127A (es)
CN (1) CN101815526B (es)
AR (1) AR068428A1 (es)
AU (1) AU2008297213B2 (es)
BR (1) BRPI0816330A2 (es)
CA (1) CA2699467A1 (es)
CL (1) CL2008002727A1 (es)
CO (1) CO6270336A2 (es)
DK (1) DK2783694T3 (es)
ES (1) ES2670859T3 (es)
GB (1) GB0717864D0 (es)
HU (1) HUE038953T2 (es)
MX (1) MX2010002025A (es)
NO (1) NO2783694T3 (es)
PE (1) PE20090682A1 (es)
PL (1) PL2783694T3 (es)
PT (1) PT2783694T (es)
RU (1) RU2466737C2 (es)
SG (1) SG187401A1 (es)
TR (1) TR201807414T4 (es)
TW (1) TWI548646B (es)
WO (1) WO2009034041A2 (es)
ZA (1) ZA201000914B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101048181A (zh) * 2004-08-13 2007-10-03 巴里·J·马沙尔 细菌递送系统
EP2191849B1 (en) * 2007-09-26 2018-08-01 National Cerebral and Cardiovascular Center Drug for suppressing pathogen occurring in vivo
US8012466B2 (en) * 2008-01-31 2011-09-06 University Of Iowa Research Foundation Immunogenic compositions for activating γδ T cells
JP5344558B2 (ja) * 2008-10-31 2013-11-20 国立大学法人 東京医科歯科大学 カチオン性ナノゲルを用いる粘膜ワクチン
FR2955393B1 (fr) * 2010-01-18 2015-12-11 Inst Rech Developpement Ird Methode pour evaluer l'efficacite de strategies de lutte anti-vectorielle dans le controle du paludisme et des arboviroses
KR101297037B1 (ko) * 2010-03-26 2013-08-14 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
US9701729B2 (en) 2013-03-08 2017-07-11 Taiho Pharmaceutical Co., Ltd. Peptide having 5 linked CTL epitopes
JP6406647B2 (ja) * 2013-07-02 2018-10-17 公益財団法人がん研究会 細胞性免疫誘導ワクチン
RU2636549C1 (ru) 2013-10-21 2017-11-23 Тайхо Фармасьютикал Ко., Лтд. Новый пептид, имеющий 4 связанных ctl-эпитопа
CN104356216B (zh) * 2014-10-09 2017-03-01 昆明医科大学 版纳绳蚋防御肽SibaDef及其基因和应用
WO2016126457A1 (en) * 2015-02-02 2016-08-11 Yale University Mosquito saliva protein malaria vaccine
US10570194B2 (en) 2015-08-06 2020-02-25 Grifols Worldwide Operations Limited Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)
US9913903B2 (en) 2015-08-06 2018-03-13 Grifols Worldwide Operations Limited Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM
JP6893765B2 (ja) * 2016-07-15 2021-06-23 森山 雅美 人以外の陸上動物用のウイルス感染症に対する抗体誘導剤とその補助剤
CN107236028B (zh) * 2017-07-05 2020-12-04 贵州医科大学 白纹伊蚊唾液34K2重组蛋白在DENV2感染HaCaT细胞中的应用
TWI805792B (zh) 2018-06-29 2023-06-21 日商大鵬藥品工業股份有限公司 抗腫瘤劑及其評估方法
EP4013411A4 (en) * 2019-08-13 2023-08-16 Tata Consultancy Services Limited PREDIABETES RISK ASSESSMENT SYSTEM AND METHODOLOGY
US20220290248A1 (en) * 2019-08-13 2022-09-15 Tata Consultancy Services Limited System and method for assessing the risk of colorectal cancer
KR102615021B1 (ko) * 2021-10-14 2023-12-20 주식회사 메디트 3차원 스캐너의 스캔 이미지 정렬 방법, 장치 및 명령을 기록한 기록매체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039958A2 (en) 2002-10-29 2004-05-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia longipalpis polypeptides and methods of use

Also Published As

Publication number Publication date
CA2699467A1 (en) 2009-03-19
NO2783694T3 (es) 2018-07-28
JP2016135767A (ja) 2016-07-28
USRE47222E1 (en) 2019-02-05
CN101815526B (zh) 2014-03-19
CN101815526A (zh) 2010-08-25
TW200920398A (en) 2009-05-16
JP5981883B2 (ja) 2016-08-31
ZA201000914B (en) 2011-04-28
PL2783694T3 (pl) 2018-10-31
PE20090682A1 (es) 2009-06-22
AU2008297213B2 (en) 2013-01-24
CO6270336A2 (es) 2011-04-20
SG187401A1 (en) 2013-02-28
JP2013240330A (ja) 2013-12-05
EP2783694A2 (en) 2014-10-01
TR201807414T4 (tr) 2018-06-21
US20100297187A1 (en) 2010-11-25
CL2008002727A1 (es) 2009-03-06
EP2783694A3 (en) 2015-01-07
EP2182972A2 (en) 2010-05-12
RU2010114597A (ru) 2011-10-20
DK2783694T3 (en) 2018-06-14
EP2567706A2 (en) 2013-03-13
AR068428A1 (es) 2009-11-18
EP2567706A3 (en) 2013-06-12
HUE038953T2 (hu) 2018-12-28
ES2670859T3 (es) 2018-06-01
EP2783694B1 (en) 2018-02-28
PT2783694T (pt) 2018-06-07
WO2009034041A3 (en) 2009-06-25
EP2407172A1 (en) 2012-01-18
BRPI0816330A2 (pt) 2015-04-14
JP6227018B2 (ja) 2017-11-08
AU2008297213A1 (en) 2009-03-19
US8986703B2 (en) 2015-03-24
WO2009034041A2 (en) 2009-03-19
RU2466737C2 (ru) 2012-11-20
GB0717864D0 (en) 2007-10-24
TWI548646B (zh) 2016-09-11
JP2010539127A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
MX2010002025A (es) Secuencias y composiciones peptidicas.
NZ597923A (en) Protein glycosylation
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
CA2563675A1 (en) Recombinantly modified plasmin
NZ596981A (en) Compositions and methods for the treatment of tumor of hematopoietic origin
Sanz et al. Molecular cloning of disintegrins from Cerastes vipera and Macrovipera lebetina transmediterranea venom gland cDNA libraries: insight into the evolution of the snake venom integrin-inhibition system
Evans Jr et al. Helicobacter pylori CagA: analysis of sequence diversity in relation to phosphorylation motifs and implications for the role of CagA as a virulence factor
BRPI0511429A (pt) proteìna de ligação à fibronectina (fnb) isolada, alterada de staphylococcal aureus (s. aureus); fnb isolada, alterada; composição imunogênica; método para imunizar um vertebrado contra s. aureus; vetor de expressão; célula hospedeira recombinante; método para produzir uma fnb alterada; método para induzir uma resposta imunológica em um vertebrado; proteìna isolada, alterada de ligação à fibronectina (fnb) de staphylococcal aureus (s. aureus); e molécula isolada de ácido nucléico que codifica uma fnb alterada de s. aureus
Shibata et al. Improvement of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide
Kawaguchi et al. Conservation of the egg envelope digestion mechanism of hatching enzyme in euteleostean fishes
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
Soni et al. Peptides Containing meso‐Oxa‐Diaminopimelic Acid as Substrates for the Cell‐Shape‐Determining Proteases Csd6 and Pgp2
ATE357526T1 (de) Modifizierte hcv peptid-impfstoffe
WO2008155363A3 (en) Identification of new isoforms of the mhc-class i specific receptor cd160 and uses thereof
Brinkworth et al. Structural analysis of the catalytic site of AcCP-1, a cysteine proteinase secreted by the hookworm Ancylostoma caninum
Tomkinson et al. The insert within the catalytic domain of tripeptidyl‐peptidase II is important for the formation of the active complex
Ota et al. Molecular cloning of two toxic phospholipases A2 from the crown-of-thorns starfish Acanthaster planci venom
TH124682A (th) ลำดับเพพไทด์และองค์ประกอบ
Matsuo et al. Cloning and expression of the ferredoxin gene from extremely halophilic archaeon Haloarcula japonica strain TR-1
Shen et al. Subunit interaction and regulation of activity through terminal domains of the family D DNA polymerase from Pyrococcus horikoshii
Barzik et al. Crystallization and preliminary X-ray analysis of the EVH1 domain of Vesl-2b
WO2006090282A3 (en) Recombinant inhibitor proteins of an hk14 protease and use thereof
DE602005016417D1 (de) Neue polypeptide zur in-vintro-isolierung und vorbeugung von infektionen mit legionella pneumophila
WO2004009775A3 (en) Methods and compositions relating to chimeric nicotinic receptor subunits

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration